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The hydrolysis of ceramides in yeast is catalysed by the
alkaline ceramidases Ypc1p and Ydc1p, two highly homologous
membrane proteins localized to the ER (endoplasmic reticulum).
As observed with many enzymes, Ypc1p can also catalyse
the reverse reaction, i.e. condense a non-esteriﬁed fatty acid
with PHS (phytosphingosine) or DHS (dihydrosphingosine) and
thus synthesize ceramides. When incubating microsomes with
[3H]palmitate and PHS, we not only obtained the ceramide
PHS–[3H]C16:0, but also a more hydrophobic compound,
which was transformed into PHS–[3H]C16:0 upon mild base
treatment. The biosynthesis of a lipid with similar characteristics
could also be observed in living cells labelled with
[14C]serine. Its biosynthesis was dependent on the diacylglycerol
acyltransfereases Lro1p and Dga1p, suggesting that it consists
of an acylceramide. The synthesis of acylceramide could also
be monitored using ﬂuorescent NBD (7-nitrobenz-2-oxa-1,3-
diazole)–ceramides as an acceptor substrate for microsomal
assays. The Lro1p-dependent transfer of oleic acid on to NBD–
ceramide was conﬁrmed by high-resolution Fourier transform and
tandem MS. Immunopuriﬁed Lro1p was equally able to acylate
NBD–ceramide. Lro1p acylates NBD–ceramide by attaching a
fatty acid to the hydroxy group on the ﬁrst carbon atomof the long-
chain base. Acylceramides are mobilized when cells are diluted
into fresh medium in the presence of cerulenin, an inhibitor of
fatty acid biosynthesis.
Key words: acylceramide, acyltransferase, detoxiﬁcation, DGA1,
LRO1, triacylglycerol.
INTRODUCTION
Sphingolipids are essential structural components of cell
membranes that also have messenger functions regulating
the proliferation, survival and death of cells. The yeast
sphingolipids consist of LCBs (long-chain bases), LCB-1-
phosphates, ceramides, IPCs (inositolphosphorylceramides) and
their mannosylated derivatives [1]. Sphingolipid synthesis
begins in the ER (endoplasmic reticulum), where serine
palmitoyltransferase uses serine and a fatty acyl-CoA to
make 3-oxo-sphinganine, which is then converted into DHS
(dihydrosphingosine; sphinganine). DHS is then hydroxylated
at C4 by Sur2p yielding its 4-hydroxy derivative PHS
(phytosphingosine; 4-hydroxysphinganine). Ceramides are made
in the ER, whereas the biosynthesis of IPCs and more complex
sphingolipids occurs in the Golgi [2]. Thus ceramide is an
intermediate in the formation of complex sphingolipids. In
mammalian cells, many reports have documented the important
role of ceramides as signalling molecules [3].
In the yeast Saccharomyces cerevisiae the biosynthesis of
ceramide ismainly achieved by the acyl-CoA-dependent ceramide
synthase LAG1 and its close homologue LAC1, formerly known as
longevity assurance genes [4,5]. Ceramides then can follow any
one of several pathways, as indicated in Figure 1. Ceramides
can also be hydrolysed by Ypc1p and Ydc1p, two alkaline
ceramidases that display more then 50% of homology over their
entire amino acid sequence and reside in the ER, where Lag1p and
Lac1p are also localized. Ypc1p catalyses, in vitro and in certain
instances in vivo, the reverse reaction, i.e. the condensation of
non-esteriﬁed fatty acids with PHS or DHS [6]. Ydc1p, in contrast
with Ypc1p, has been shown to hydrolyse only DHS-containing
ceramides and exhibits only veryweak reverse activity in vitro, but
seems to be able to work in the reverse direction in vivo [5,7–9].
Like many organisms, yeast store neutral lipids in the
form of LDs (lipid droplets). Synthesis of neutral lipids
and thus LD biogenesis in yeast is mediated by two acyl-
CoA:sterol acyltransferases, Are1p and Are2p, and by Lro1p
and Dga1p, which acylate DAG (diacylglycerol) to produce TAG
(triacylglycerol). All of these enzymes are present in the ER,
except for Dga1pwhich has amuch higher speciﬁc activity in LDs
than the ER [10–12]. LRO1 accounts for the major part of TAG
biosynthesis in exponentially growing cells and is homologous
with the mammalian LCAT (lecithin cholesterol acyltransferase)
[13,14]. Lro1p transfers a fatty acid from the sn-2 position
of PE (phosphatidylethanolamine) or PC (phosphatidylcholine)
on to DAG, whereas Dga1p transfers the fatty acid from acyl-
CoA on to DAG [10,13–15]. Neutral lipid synthesis and storage
are dispensable for the viability of S. cerevisiae because an
are1are2dga1lro1 quadruple mutant is viable, makes no
storage lipids and lacks detectable LDs [14,16].
In the present paper we report on the enzymatically mediated
acylation of ceramides, a process which physiologically may
allow for ceramide storage or detoxiﬁcation.
EXPERIMENTAL
Strains, growth conditions and materials
S. cerevisiae strains used are listed in Table 1 and plasmids
used are listed in Table 2. Mutant strains were generated using
standard methods for crossing of single mutants, for plasmid
transfection or gene disruption using deletion cassettes generated
Abbreviations used: CHX, cyclohexamide; DAG, diacylglycerol; DDQ, 2,3-dichloro-5,6-dicyanobenzoquinone; DHS, dihydrosphingosine; ER,
endoplasmic reticulum; FT-MS, Fourier transform MS; GFP, green ﬂuorescent protein; IPC, inositolphosphorylceramide; LCAT, lecithin cholesterol
acyltransferase; LCB, long-chain base; LD, lipid droplet; MMA, monomethylamine; MS/MS, tandem MS; NBD, 7-nitro-2-oxa-1,3-diazole; PC,
phosphatidylcholine; PE, phosphatidylethanolamine; PHS, phytosphingosine; PLA2, phospholipase A2; TAG, triacylglycerol; WT, wild-type; YPD, 1%
(w/v) yeast extract/2% (w/v) peptone/2% (w/v) glucose; YPG, 1% (w/v) yeast extract/2% (w/v) tryptone/ 2% (w/v) galactose.
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Table 1 Yeast S. cerevisiae strains
Strains Genotype Reference
BY4742 MATα his31 leu20 lys20 ura30 EUROSCARF
WT.vector (FBY5218) As BY4742 but also containing pRS415 The present study
WT.YPC1 (FBY5215) As BY4742 but also containing pYPC1-LEU2 The present study
lro1.YPC1 (FBY5219) As BY4742, but lro1::kanMX and also containing pYPC1-LEU2 The present study
lro1.YPC1.LRO1 (FBY5277) As BY4742, but lro1::kanMX and also containing pYPC1-URA3 and pLRO1-LEU2 The present study
ypc1ydc1.vector (FBY5322) MATα can1::STE2pr-Sp_his5 lyp1 his31 leu20 ura30 met150 ypc1::LEU2 ydc1::natMX containing pNP302 The present study
ypc1ydc1.YPC1 (FBY5321) MATα can1::STE2pr-Sp_his5 lyp1 his31 leu20 ura30 met150 ypc1::LEU2 ydc1::natMX containing pYPC1-URA3 The present study
are1are2lro1.DGA1 (RSY3292) As BY4742 but are1::kanMX are2::kanMX trp1::URA3 lro1::loxP GAL1UAS-GFP-DGA1::HIS3 [12]
are1are2dga1.LRO1 (RSY3202) As BY4742 but are1::kanMX are2::kanMX trp1::URA3 dga1::loxP GAL1UAS -GFP-LRO1::HIS3 R. Schneiter
are1lro1dga1.ARE2 (RSY3492) As BY4742 but lro1::kanMX dga1::loxP are1::loxP GAL1UAS-ARE2::HIS3 R. Schneiter
scs7 BY4742, but scs7::kanMX EUROSCARF
isc1 BY4742, but isc1::kanMX EUROSCARF
are1are2dga1.LRO1.DGA1 (RSY4360) As BY4742 but are1::kanMX are2::kanMX trp1::URA3 dga1::loxP GAL1UAS-LRO1::TRP1 containing pGAL1-GFP-DGA1-URA3 R. Schneiter
Figure 1 Ceramide biosynthesis and utilization in yeast
The various metabolic pathways generating and consuming ceramides are shown. Gene names
are in italic. The novel pathway generating acylceramides described in the present paper is in
bold.
Table 2 Plasmids
Plasmid Details Reference
pRS415 CEN ARS LEU2 [45]
pNP302 CEN ARS URA3, ADH1 promoter C. De Virgilio
pNP308 CEN ARS LEU2, ADH1 promoter C. De Virgilio
pYPC1-LEU2 YPC1 in pNP308 The present study
pYPC1-URA3 YPC1 in pNP302 The present study
pLRO1-LEU2 LRO1 behind its natural promoter in pRS415 R. Schneiter
by PCR. Cells were grown on rich medium {YPD [1% (w/v)
yeast extract/2% (w/v) peptone/2% (w/v) glucose] or YPG [1%
(w/v) yeast extract/2% (w/v) tryptone/ 2% (w/v) galactose]}, or
synthetic minimal or complete media [YNB (yeast nitrogen base);
United States Biological) containing 2% (w/v) glucose (D) or
galactose (G) as a carbon source. All experiments were performed
with cells growing exponentially. Where indicated, medium or
buffers were supplemented with CHX (cycloheximide), myriocin,
cerulenin, palmitate or L-α-PC from egg yolk, all obtained
from Sigma. [14C]Serine and [3H]palmitate were from American
Radiolabeled Chemicals. DHS, PHS, ﬂuorescent ceramides (C12–
NBD–PHS and C6–NBD–DHS; NBD is 7-nitrobenz-2-oxa-1,3-
diazole) and fatty acyl-CoAs were from Avanti Polar Lipids.
C6–NBD–sphingosine was from Invitrogen. Monomethylamine
(33% in ethanol) was from Fluka. Dynabeads®–Protein G
was from Invitrogen. Zymolyase-20T (Arthtrobacter luteus) was
from Seikagaku Biobusiness.Mousemonoclonal anti-GFP (green
ﬂuorescent protein) antibodies were fromRoche Diagnostics. The
anti-mouse IgG–peroxidase conjugate was from Sigma.
Construction of plasmids
To construct plasmids containing YPC1, the open reading frame
was ampliﬁed by PCR using the oligonucleotides 5′-CCT-
GGGATCCATGGGAATATTTCGTTGGAACTATCC-3′ and 5′-
CGCCGCGGCCGCTTACTTCTCCTTTTTAACTTC-3′ and ge-
nomic DNA from WT (wild-type) BY4742 cells. PCR products
were doubly digested with NotI and BamHI and ligated into the
similarly digested pNP308 or pNP302 vectors to generate pYPC1-
LEU2 and pYPC1-URA3. DNA sequencing of inserts conﬁrmed
the correct sequence of YPC1.
Protein analysis
Proteins were extracted by mild alkali treatment and subsequent
boiling of cells in a standard electrophoresis loading buffer [17].
Proteins were resolved by SDS/PAGE and detected by Western
blotting using standard procedures.
Mass spectrometric lipid analysis
Microsomes were extracted with chloroform/methanol [2:1 (v/v)]
[18]. Lipid extracts were analysed in negative-ion mode by direct
infusion MS using an LTQ Orbitrap XL mass spectrometer
equipped with the automated nanoﬂow ion source Triversa
NanoMate (Advion Biosciences) [18]. C6–NBD–DHS and its
acyl-derivatives were detected by high-resolution FT-MS (Fourier
transform MS) using a target mass resolution of 100 000. In addi-
tion, the identity of detected C6–NBD–DHS and acyl-derivatives
was conﬁrmed by ion-trap MS/MS (tandem MS) analysis.
Metabolic labelling of cells with [14C]serine, lipid extraction,
mild base treatment and TLC
Cells were grown in synthetic minimal medium. Then 3.0 D600
units of exponentially growing cells (3 ml of a culture having
a D600 of 1.0) were harvested and resuspended in 250 μl of the
same medium supplemented with 10 μg/ml CHX. After 10 min
of pre-incubation, 4 μCi of [14C]serine was added and cells were
incubated for 40 min at 30 ◦C. Then the samples were diluted
with 750 μl of fresh minimal medium supplemented with CHX
and labelling was continued for a further 120 min. Labelling
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was terminated by adding sodium azide and sodium ﬂuoride
(10 mM ﬁnal concentrations) and chilling cells on ice. Cells were
resuspended in chloroform/methanol [2:1 (v/v)] and broken with
glass beads in the cold. The extract was kept apart and the pellet
was re-extracted sequentially with chloroform/methanol [1:1
(v/v)] and ethanol/water/diethyl ether/putridine/25% ammonium
hydroxide (15:15:5:1:0.018, by vol.), which achieves quantitative
extraction of all complex sphingolipids [19]. Extracts were
combined and solvent was evaporated under vacuum in a
rotary evaporator. Incorporation into lipids usually amounted
to 5% of radioactivity added. Where indicated, lipids were
subjected tomild base hydrolysiswith sodiumhydroxide orMMA
(monomethylamine). For this, lipids were resuspended in 200 μl
of chloroform/methanol/water (10:10:3, by vol.), 40 μl of 0.6 M
sodium hydroxide in methanol (ﬁnal concentration of 0.1 M) was
added, and samples were incubated for 1 h at 37 ◦C. Hydrolysis
was stopped with 40 μl of 0.8 M acetic acid in methanol. Control
samples were incubated on ice and at the end of the incubation
supplemented with 40 μl of 0.8 M acetic acid plus 40 μl of
0.6 M sodium hydroxide. The desalted lipids were resolved by
ascending TLC on silica gel plates. Alternatively, lipids were
resuspended in 400 μl ofMMA (33% in ethanol) or, as a negative
control, inmethanol, and incubated at 53 ◦C for 1 h. Then, solvents
were evaporated under vacuum. All lipids were resolved by
ascending TLC on silica gel plates after having been desalted by
Folch partitioning as described previously [20]. Unless indicated
otherwise, extracts of microsomes were developed with solvent
1 (chloroform/methanol/25% ammonium hydroxide, 9:2:0.5,
by vol.) and extracts from metabolically labelled cells were
developed with solvent 2 (chloroform/methanol/2 M ammonium
hydroxide, 40:10:1, by vol.). When the untreated and deacylated
lipid extract was run side by side, material from an equivalent
number of cells was spotted, whether we analysed extracts
from metabolic labellings or microsomal labelling reactions (see
below). Radioactivity was detected and quantiﬁed by one- and
two-dimensional radioscanning using aBerthold radioscanner and
visualized by ﬂuorography or radioimaging using the Bio-Rad
Molecular Imager FX. Unless otherwise stated, radioactivity in
individual spots was given as the percentage of total radioactivity
detected by radioscanning in the corresponding lane, except for
acylceramides. In the case of acylceramides, the counts of residual
mild-base-resistant lipid co-migratingwith acylceramides, aswell
as of an occasional trace of material co-migrating with fatty acids,
were deducted from the acylceramide signal as follows:
Percentage of acylceramides
= (acylceramide untreated − [acylceramide deacylated
+ fatty acid deacylated]/total counts untreated) × 100.
Preparation of microsomes
Microsomes were prepared from yeast cells grown in synthetic
complete media. Brieﬂy, as described previously [6], cells were
homogenized in a lysis buffer containing 25 mM Tris/HCl
(pH 7.4), 1 mM PMSF and Roche protease inhibitor cocktail.
Unbroken cells and cell debris were removed by centrifugation
at 500 g for 5 min. The membrane fraction was sedimented
by centrifuging the supernatant at 16000 g for 40 min at 4 ◦C.
The microsomes were resuspended in assay buffer A containing
25 mMTris/HCl (pH 8.0), 5 mMCaCl2 and 1 mMPMSF. In most
experiments, boiled microsomes (100 ◦C for 10 min) were used as
a negative control. Protein concentrations were determined using
Bradford reagent (Bio-Rad Laboratories).
Microsomal assay of reverse ceramidase using [3H]palmitate
The reverse ceramidase activity was measured as described
previously [21] with the following modiﬁcations: 10 μl of 1 mM
PHS or DHS, 3 μCi of [3H]palmitate (60 Ci/mmol) and 0.4
nmol of non-radioactive palmitate were dried under vacuum in
a rotary evaporator. Dried lipids were dissolved in 20 μl of buffer
A by water bath sonication. The reactions were started by adding
microsomes corresponding to 50 μg of protein to attain a ﬁnal
volume of 50 μl. Samples were incubated at 30 ◦C for 1 h at
300 rev./min on a tube shaker. The reactions were terminated by
adding 300 μl of chloroform/methanol [2:1 (v/v)].
Microsomal assays using NBD–ceramides
NBD-containing ceramides (C12–NBD–PHS, C6–NBD–DHS or
C6–NBD–sphingosine) were bound to BSA using an established
procedure [22], which was modiﬁed as follows. For ten standard
reactions, 100 nmol of NBD–ceramide were dissolved in 20 μl of
ethanol and added to 200 μl of buffer A containing 40 mg/ml
of fatty-acid-free BSA giving an NBD–ceramide to BSA molar
ratio of 1:1. The solution was incubated on a wheel at 4 ◦C for
2 h. Microsomal pellets were dissolved in buffer A supplemented
with 10 mg/ml of fatty-acid-free BSA, the ﬁnal concentration
of microsomal protein being 5.0 mg/ml. The reactions were
initiated by adding 50–100 μg of microsomes to 10 nmol of
NBD–ceramide in a ﬁnal volume of 50 μl containing 10 mg/ml
BSA. Reaction mixtures were incubated at 30 ◦C for 2 h and then
stopped by adding 300 μl of chloroform/methanol [2:1 (v/v)].
Lipids were extracted, treated or not with mild base, desalted and
resolved by TLC. Products of NBD–ceramide conversion were
identiﬁed as ﬂuorescent bands and quantiﬁed with a FluorChem
8900 ﬂuorescence detector (Witec).
Immunopuriﬁcation of Lro1p–GFP on Dynabeads®–Protein G
RSY3202 cells were grown on YPG media. Cells were collected,
treated with zymolyase and spheroplasts were lysed with a
Dounce homogenizer in buffer B [20 mM Hepes (pH 6.8), 0.2 M
sorbitol, 50 mM potassium acetate, 2 mM EDTA and protease
inhibitors]. Microsomes were sedimented by centrifugation at
16000 g for 30 min at 4 ◦C and solubilized in buffer B with
0.5% Triton X-100 for 30 min on ice whereupon non-solubilized
material was removed by centrifugation. Next, 4 μg of mouse
anti-GFP antibodies were bound to 50 μl (1.5 mg) of Dynabeads
and the washed beads were incubated with 500 μg of solubilized
microsomal protein for 30 min at room temperature (25 ◦C) on
a rotating wheel. Beads were sedimented using a magnet, the
supernatant containing non-bound proteins was removed and
the beads were washed three times with 0.5% Triton X-100 in
PBS using magnetic sedimentation. Acylceramide synthesis was
measured in a ﬁnal volume of 90 μl for 2 h at room temperature.
The assay contained buffer A, BSA (10 mg/ml), PC (450 μM),
C6–NBD–DHS (50 μM), a ﬁnal concentration of 0.5% Triton
X-100 and 20 μl of Dynabeads–Lro1p–GFP conjugate or super-
natant containing non-bound proteins. For protein determination,
puriﬁed Lro1p–GFP was eluted from beads at pH 2.5.
RESULTS
In vitro microsomal assay of ceramide synthase activity reveals
Lro1p-dependent ceramide esteriﬁcation
As described previously [6], reverse ceramidase activity of Ypc1p
can be measured by incubating microsomes with [3H]palmitate
and non-radioactive LCBs (Figures 2A and 2B). The Rf of

ht
tp
://
do
c.
re
ro
.c
h
Figure 2 Lro1p-dependent ceramide esteriﬁcation in microsomes
(A) Microsomes were prepared from BY4742 (WT) and lro1Δ cells carrying an empty vector or vectors with open reading frames of the genes indicated after the dots. The reverse activity of Ypc1p
was measured by incubating native (n) or boiled (b) microsomes with [3H]palmitate and DHS (D) or PHS (P) as substrates. Lipids were extracted, resolved by TLC and quantiﬁed by radioscanning.
Presumed acylceramides are marked with an asterisk. A representative experiment from three experiments, all giving the same result, is shown. (B) Counts present in ceramides and putative
acylceramides of (A) were quantiﬁed by radioscanning and plotted as a percentage of the total counts present in the lane. (C) Presumed acylceramides and ceramides obtained in an in vitro assay
with microsomes from WT vector cells using DHS (lane 1) or PHS (lane 2) as substrates were labelled α, β , γ and δ. These bands were scraped off of the TLC plate, extracted and treated with mild
base (sodium hydroxide) or incubated as a control. Hydrolysis products were desalted and separated by TLC. The identity of lipids α–δ on the basis of this experiment is indicated at the bottom.
ceramides is higher when DHS is used as a substrate than when
PHS is used (Figure 2A) and the reaction is much faster when
YPC1 is overexpressed (Figure 2A, lanes 1 and 2 compared
with lanes 4 and 5, and Figure 2B). (Microsomes from Ypc1p-
overexpressing cells actually represent an easy and cheap way to
generate radiolabelled ceramides.) The reverse ceramidase assay
invariably also generated a lipid, which migrated faster than
ceramides, pointing to its higher hydrophobicity as compared
with ceramides (marked with an asterisk in Figure 2A). We
will show below that this species is likely to be a 1-O-acylated
ceramide. O-acylated ceramides, as well as ceramides, did not
appear when boiled microsomes were used (Figure 2A, lanes
3, 6, 9 and 12). The putative acylceramides were scraped
off the TLC plate and treated with sodium hydroxide for
saponiﬁcation (Figure 2C). Upon mild base hydrolysis the
presumed acylceramides α and γ , generated using either DHS
or PHS as substrates, yielded the corresponding ceramides (lanes
3, 4, 7 and 8); the ceramides themselves (β and δ) remained
stable in the presence of sodium hydroxide (lanes 5, 6, 9 and 10),
in agreement with the idea that the lipids marked with an asterisk
in Figure 2(A) are acylceramides.
Acylceramide had previously been shown to be made
by mammalian cells when microsomes were incubated with
N-acetyl-[3H]sphingosine. The enzyme catalysing the synthesis
of O-acylceramide in mammals was identiﬁed as LPLA2, a
soluble lysosomal enzyme working mainly as an acid PLA2
(phospholipase A2), but able to also use ceramide rather than
water as an acceptor substrate [23]. A BLAST search showed
that its closest homologue in S. cerevisiae is Lro1p. Indeed,
the synthesis of acylceramides was strongly reduced in lro1Δ
cells, suggesting that LRO1 deletion abolished ceramide acylation
(Figure 2A, lanes 7 and 8 comparedwith lanes 4 and 5).Moreover,
the complementation of the lro1Δ mutant with a single copy
plasmid bearing LRO1 under its native promoter completely
rescued the acylation of ceramides (Figure 2A, lanes 10 and
11).Wewondered whether the second yeast DAG acyltransferase,
Dga1p, is also capable of catalysing the synthesis of acylceramide
in vitro. To test for this we incubated microsomes of an lro1Δ
strain overexpressing YPC1 with PHS and [3H]palmitate as in
Figure 2(A), lane 8, in order to allow for the formation of
labelled ceramides. At the end of the incubation, the reaction
was supplemented with different acyl-CoAs as acyl donors
for Dga1p and the incubation was continued for a further
1 h (Supplementary Figure S1 at http://www.BiochemJ.org/
bj/447/bj4470103add.htm). No acylceramide synthesis was
detected in this experiment. Although Dga1p is able to acylate
ceramides in vivo (see below), reasons for this negative
in vitro experiment could be that Ypc1p and Dga1p reside in
different subcompartments of the ER, which end up in different
microsomes, i.e. that microsomes generating [3H]ceramide did
not contain enough Dga1p activity. Indeed, Dga1p activity is
concentrated in LDs, whereas Lro1p is mainly present in the
ER membrane [10,13] (R. Schneiter, personal communication).
NBD–ceramides are acylated in vitro by Lro1p
To further support the idea that Lro1p is capable of O-acylating
ceramides, we tested the capacity of microsomes to acylate
ﬂuorescent ceramides. Figure 3(A) demonstrates that up to 25%
of C12–NBD–PHS was acylated by microsomes in a 2 h assay,
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Figure 3 In vitro acylation of NBD–ceramides
(A) Native or boiled microsomes from the indicated strains were incubated for 2 h at 30◦C in
the presence of C12–NBD–PHS, i.e. a ceramide containing an NBD–C12 fatty acid linked to PHS.
Lipids were extracted, subjected or not to alkaline hydrolysis and resolved by TLC. Lane 17
contains the C12–NBD–PHS standard as received from Avanti Polar Lipids. The bottom panel
represents the quantiﬁcation of acylceramide and ceramide as a percentage of total ﬂuorescence
in each lane. (B) Results from (A) were quantiﬁed by averaging ﬂuorescent signals of ceramides
and acylceramides of lanes 1, 5, 9 and 13. (C) The indicated mutants were grown on glucose or
galactose overnight. Microsomes were labelled as described above, but using C6–NBD–DHS,
i.e. anNBD-C6 fatty acid linked to the nitrogen of DHS.Microsomes of are1are2lro1.DGA1
and are1lro1dga1.ARE2 strains were additionally supplemented with 5 nmol of C16:0-CoA
and C18:1-CoA respectively. b, boiled; Cer, ceramide; glc, glucose; gal, galactose; n, native.
and the extent of this acylation was independent of the presence
of Ypc1p in the ypc1Δydc1Δ background used in the present
experiment (Figures 3A and 3B). However, when Ypc1p was
present, we observed a faint signal, presumably corresponding
to C12–NBD fatty acid, the product of the ceramidase activity
of Ypc1p (Figure 3A, lanes 1 and 5). Qualitatively similar
results were obtained with C6–NBD–DHS, having a shorter
NBD–fatty acid and a different LCB (Figure 3C, lanes 5
and 25, and Figure 4D), whereby no ceramidase activity was
detected, possibly because YPC1 was not overexpressed as in
Figure 3(A). Acylation, as well as hydrolysis of NBD–ceramides,
were observed to a much lower degree when boiled micro-
somes were used in the reaction (Figure 3A, lanes 3, 7, 11
and 15 compared with lanes 1, 5, 9 and 13, and Figure 3C).
The rate of C12–NBD–PHS hydrolysis by Ypc1p-containing
microsomes in Figure 3(A) amounted to approximately 1%
of total ﬂuorescence (lanes 1 and 5), i.e. it was 6-fold faster
than the hydrolysis by yeast microsomes strongly overexpressing
human alkaline ceramidase [21]. Although we did not study the
kinetics of the metabolism of NBD–ceramides in microsomes, it
nevertheless is striking to observe that acylation of this artiﬁcial
substrate by endogenous levels of Lro1p is 20-fold faster than
its hydrolysis by the overexpressed Ypc1p (Figure 3A, lanes 1
and 5), whereby the conditions used for acylceramide synthesis
in Figure 3(A) are the same as the ones optimized for measuring
Ypc1p-mediated ceramidase activity [6].Mild base treatment also
released approximately 1% of the amide-bound NBD–C12 fatty
acids (Figure 3A, lanes 4, 8, 12 and 16 compared with lanes 3, 7,
11 and 15).
To see which enzymes were responsible for NBD–ceramide
acylation, we took advantage of are1are2lro1.DGA1,
are1are2dga1.LRO1 and are1lro1dga1.ARE2 strains,
in which the endogenous DGA1, LRO1 or ARE2 gene is placed
behind the GAL1-promoter respectively, while all other DAG- or
sterol-acyltransferases are deleted. These mutants were cultured
on glucose or galactose to repress the expression or induce the
overexpression of LRO1, DGA1 or ARE2 respectively. (Are2p
accounts for most of the sterol acyltransferase activity, when yeast
cells grow in the presence of oxygen [24].) Massive amounts of
acylated C6–NBD–DHS were made by microsomes derived from
cells overexpressing Lro1p after having been grown on galactose,
much more than from cells grown on glucose (Figure 3C, lanes
1 and 5). In contrast, overexpression of Are2p or of Dga1p did
not result in signiﬁcant microsomal ceramide acylation in the
presence of acyl-CoA (Figure 3C).
Identiﬁcation of the hydroxy group that is acylated by Lro1p
PHS has hydroxy groups on carbon atoms 1, 3 and 4, and DHS
on carbon atoms 1 and 3. To decide whether ceramides are
acylated on the carbon atom 1 or 3 of the LCB, we used a
procedure previously employed by others [25], which requires
the use of ceramides containing sphingosine rather than DHS
or PHS. Sphingosine is a dehydrogenated DHS with a 4
double bond (Figure 4A). We found that yeast microsomes
efﬁciently acylate C6–NBD–sphingosine (Figure 4B). Acyl-C6–
NBD–sphingosine and unreacted C6–NBD–sphingosine were
scraped from a TLC plate and treated with DDQ (2,3-dichloro-
5,6-dicyanobenzoquinone) [25]. DDQ oxidizes α-β-unsaturated
alcohols to ketones. Thus an hydroxy group in the C3 position
of sphingosine will be oxidized to a ketone group, unless it
is acylated (Figure 4A). After treatment with DDQ, all of the
C6–NBD–sphingosine was converted into corresponding 3-oxo-
forms, which have a higher TLCmobility, as described previously
[25] (Figure 4C, lanes 1 and 2). The same was true for acyl-C6–
NBD–sphingosine (Figure 4C, lanes 3 and 4). Controls showed
that C6–NBD–DHS and acyl-C6–NBD–DHS lacking the 4
double bond were not oxidized (Figures 4D and 4E). These
results suggest that the microsomal ceramide esteriﬁcation by
Lro1p involves the hydroxy group on C1, not C3, of the LCB.
Lro1p transfers oleic acid on to NBD–ceramide
If Lro1p is the enzyme that acylates ceramides, we would
expect that it transfers on to ceramides the same C16 and
C18 fatty acids as to DAG. To test this, microsomes from
WT cells were incubated with the ceramide analogue C6–
NBD–DHS. Microsomes were subsequently extracted and
analysed by high-resolution FT-MS and structural analysis
by ion-trap MS/MS [18,26]. FT-MS analysis detected a
molecular ion with m/z 840.6215 in microsomes incubated with
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Figure 4 Lro1p acylates the hydroxy group at C1 of ceramides
(A) Formula of D-erythro-sphingosine. (B) The experiment shown in Figure 3(C), lane 5 was
repeated using C6–NBD–sphingosine as a substrate instead of C6–NBD–DHS (lanes 1 and 2).
Lane 3 contains the C6–NBD–sphingosine as obtained from Invitrogen. Lipids were extracted
and resolved by TLC. (C) Acyl-C6–NBD–sphingosine and C6–NBD–sphingosine from (B) were
scraped off of the plate. Lipids were extracted from the silica and incubated for 48 h at 37◦C
with or without 3% DDQ in 40 μl of dioxane and then dried in a rotary evaporator as described
previously [25]. The lipids were resuspended in 3 ml of chloroform/methanol [2:1 (v/v)] and
0.6 ml of 0.1 M sodium hydroxide was added. After vigorous shaking and brief centrifugation the
lower layer (organic phase) was recovered and re-extracted twice with 2 ml of methanol/0.1 M
sodium hydroxide [1:1 (v/v)] and twice more with 2 ml of methanol/water [1:1 (v/v)]. The lipids
were resolved by TLC in chloroform/methanol/glacial acetic acid (90:1:9, by vol.) and then
visualized by direct ﬂuorescence using a FluorChem ﬂuorescence detector. Oxidation of the C3
hydroxy group increases the mobility in this solvent system [25]. (D) The same experiment as in
(B) was performed using 5 or 1 nmol of C6–NBD–DHS as a substrate. (E) Acyl-C6–NBD–DHS
and C6–NBD–DHS of (D) were scraped and processed as in (C). (F) Lro1p–GFP was puriﬁed
using an anti-GFP antibody. Equivalent aliquots of puriﬁed Lro1p–GFP bound to afﬁnity beads
(lanes 5–8) or of supernatant containing non-bound microsomal proteins were incubated with
C6–NBD–DHS and PC for 2 h at room temperature. Lipids were extracted and separated on TLC
as in (C). (G) Aliquots corresponding to equivalent amounts of startingmaterial taken throughout
puriﬁcation were analysed by Western blotting using an anti-GFP antibody. b, boiled; n, native;
Sph, sphingosine.
C6–NBD–DHS, but not in microsomes without the addition
of C6–NBD–DHS or if microsomes had been boiled (Figures 5A–
5D). With a mass accuracy of 0.6 p.p.m., this molecular
ion matches the identity of the acylceramide C18:1-C6–NBD–
DHS (calculated m/z 840.6220). To conﬁrm the identity of the
C18:1-C6–NBD–DHS species we performed structural analysis
by ion-trap MS/MS. The fragment ions derived from the ion
with m/z 840.6215 could all be ascribed structural features
in the intact acylceramide ion (Supplementary Figure S2 at
http://www.BiochemJ.org/bj/447/bj4470103add.htm). Fragment-
ation thus conﬁrms the synthesis of C18:1-C6–NBD–DHS in WT
microsomes incubated with the precursor C6–NBD–DHS.
Next, to conﬁrm that Lro1p is responsible for the synthesis
of C18:1-C6–NBD–DHS, we tested whether increasing the
expression level of the enzyme would increase the production
of the acylceramide species. To this end, we monitored
the production of C18:1-C6–NBD–DHS in microsomes from
are1are2dga1.LRO1 cells overexpressing LRO1 when
cultured on galactose and in microsomes from low-level-
expressing cells cultured on glucose. We observed that the levels
of C18:1-C6–NBD–DHS were massively increased when Lro1p
was overexpressed (Figures 5E–5G). In comparison, incubating
microsomes from cells overexpressing DGA1 with C6–NBD–
DHS did not yield signiﬁcant amounts of C18:1-C6–NBD–DHS
(Figure 5H).
PE and PC, which are the preferred substrates of Lro1p, most
often carry C18:1 at their sn-2 position [27] and, as shown in
Figure 5, this species seems to be attached by microsomes in an
LRO1-dependentmanner to C6–NBD–DHS. Taken together, these
data support the idea that Lro1p is directly involved in transferring
the fatty acid from PE or PC to ceramides.
Puriﬁed Lro1p can acylate NBD–ceramide in vitro
Lro1p–GFP was immunopuriﬁed from a strain with the
chromosomal LRO1 tagged with GFP and placed under the GAL1
promoter (Figure 4G). Puriﬁed Lro1p–GFP was assayed in the
presence of NBD–ceramide and PC as shown in Figure 4(F).
Calculating how much NBD–ceramide was transformed into
acylceramide per microgram of protein during the assay
demonstrated that the ceramide acylating activity was more
than 800-fold enriched in the puriﬁed Lro1p–GFP fraction as
compared with the immunodepleted supernatant. This again
strongly suggests that the ceramide acylation reaction is carried
out by Lro1p.
Ceramide acylation also occurs in living cells
Many processes taking place in vitro have no physiological
correlate. Our calculations on the basis of concentrations of free
ceramides in cells reported in the literature [4,28] and on the
speciﬁc activity of [3H]palmitate added tomicrosomes ofWTcells
in assays of the type shown in Figure 2(A) led us to conclude that
we generated approximately 45–125 pmol of [3H]C16-ceramide in
microsomes that already contained a minimum of 50–100 pmol
of C26-ceramides. This latter estimate is probably too low, since
it can be expected that ceramides are more concentrated in ER-
derived Lro1p-containing microsomes than in the average cellular
membrane. Also, when doing reverse ceramidase assays with
WT.YPC1 microsomes as in Figure 2(A), but not adding non-
radioactive palmitate into the assays, so that only 14 pmol of
[3H]ceramide was generated, we always found that 25–30%
of ceramides appeared as acylceramides (results not shown).
This convinced us that the acylation of [3H]C16-ceramide by
microsomes observed in vitro (Figure 1A) occurred at ceramide
concentrations that were not signiﬁcantly above the physiological
range of ceramides in living cells. To gain further insight and
to see also whether C26-ceramides were acylated, we labelled
yeast cells with [14C]serine, allowing us to follow sphingolipid
metabolism in vivo. WT cells fed with [14C]serine produced a
substantial amount of a non-polar lipid migrating to the position
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Figure 5 Proﬁling of C18:1-C6–NBD–DHS by MS
(A) The indicated strains were grown on glucose or galactose overnight. Native or boiled microsomes from WT and mutants were incubated for 2 h at 30◦C in the presence or absence of
C6–NBD–DHS. Each reaction was split into two equal parts of 20 μl, each containing 25 μg of protein. Lipids extracted from one half were split and treated with methanol or MMA for alkaline
hydrolysis and analysed by TLC. b, boiled; gal, galactose; glc, glucose; n, native. (B–H) Lipid extracts of the second half of the microsomes were subjected to FT-MS analysis as described in the
Experimental section. Panels on the right-hand side depict magniﬁed spectra of those on the left-hand side. (B–H) contain samples corresponding to lanes 1, 3, 5, 7, 9, 11 and 13 of (A) as indicated.
(B) Microsomes from WT cells incubated with C6–NBD–DHS; (C) microsomes from WT cells without the addition of C6–NBD–DHS; (D) microsomes from WT cells, boiled and incubated with
C6–NBD–DHS; (E) microsomes from are1are2dga1.LRO1 cells cultured in YPG incubated with C6–NBD–DHS; (F) microsomes from are1are2dga1.LRO1 cells cultured in YPG, boiled
and incubated with C6–NBD–DHS; (G) microsomes from are1are2dga1.LRO1 cells cultured in YPD incubated with C6–NBD–DHS; and (H) microsomes from are1are2lro1.DGA1 cells
cultured with YPG incubated with C6–NBD–DHS.
of acylated ceramide (Figure 6A, asterisk). Mild base treatment
led to the disappearance of part of this lipid and the appearance
or increases of lipids considered to represent DHS-C26 and PHS-
C26-OH (Figure 6A, lanes 7 and 8). In many cases hydrolysis of
these presumably acylated ceramides was incomplete, in others
it was complete and we presently are not quite sure whether
this hydrophobic lipid is heterogeneous, containing a mild-base-
sensitive and a mild-base-resistant component, or if it is not
efﬁciently solubilized and therefore not efﬁciently hydrolysed.
As shown in Figure 6(A), we labelled the living cells with
[14C]serine for various periods of time allowing us to observe
the kinetics of acylceramide synthesis (Figure 6A). The level
of [14C]ceramides reached steady-state levels after 40 min and
thereafter slowly declined (Figure 6B). Acylceramides increased
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Figure 6 DGA1 and LRO1 make acylceramides in vivo
(A) WT cells were metabolically labelled with [14C]serine for 10–120 min. Lipids were extracted, treated with sodium hydroxide or mock-incubated and separated by TLC; o, origin. The assignment
of DHS-C26, PHS-C26 and PHS-C26-OH to distinct bands in this and following Figures is tentative and solely based on the presence or absence of major bands of the same mobility in sur2Δ, scs7Δ
and sur2Δscs7Δ cells lacking the LCB-C4-hydroxylase, the fatty acid C2-hydroxylase or both [31] (results not shown). Assignments are supported by previous data on the relative abundance
of the various IPC and ceramide species in yeast [18,30,32]. The TLC system used is mainly sensitive to the number of hydroxy groups of ceramides, not fatty acid chain length. (B) Amounts of
acylceramides and the sum of all ceramides from (A) were obtained by radioscanning and plotted as c.p.m. against time of labelling. (C) WT, are1are2lro1.DGA1 and are1are2dga1.LRO1
cells were grown overnight on glucose (glc) or galactose (gal) and then labelled with [14C]serine at 30◦C for 160 min on the same carbon source as used in the preculture. Growth on galactose led
to a drastic induction of Lro1p and Dga1p (Supplementary Figure S3 at http://www.BiochemJ.org/bj/447/bj4470103add.htm). Lipids were extracted, desalted and deacylated with sodium hydroxide
or were mock-incubated. They then were resolved by TLC. (D) Ceramides and acylceramides in (C) were quantiﬁed by radioscanning. Cer, ceramide; gal, galactose; glc, glucose; o, origin.
at maximal speed only after 40 min, when ceramides had reached
their maximal level but did not reach a plateau during the 2 h of
labelling (Figure 6B). These data are compatiblewith a continuous
acylation of part of the newly made ceramides. The same amounts
of acylceramide were also observed, when ypc1Δydc1Δ cells
were metabolically labelled, suggesting that the bulk of ceramides
that are acylated in vivo are made by Lag1p and Lac1p (results
not shown).
To see whether Lro1p, and possibly Dga1p or Are2p, were
involved in making the very hydrophobic lipid species observed
in Figure 6(A), we again used the are1are2lro1.DGA1,
are1are2dga1.LRO1 and are1lro1dga1.ARE2 strains,
in which the endogenous DGA1, LRO1 or ARE2 genes have been
placed behind the GAL1-promoter respectively. These mutants
have no LDs when grown on glucose, but induce LDs on
galactose, indicating that expression of one of the three genes
LRO1, DGA1 or ARE2 is sufﬁcient to cause the appearance
of LDs [12,16]. Accordingly, these strains were grown on
glucose or on galactose and then labelled with [14C]serine along
with WT cells (Figure 6C). LRO1 and DGA1 overexpression
was veriﬁed by Western blotting (Supplementary Figure
S3 at http://www.BiochemJ.org/bj/447/bj4470103add.htm) and
allowed the cells to produce signiﬁcant amounts of acylceramides
(Figure 6C, lanes 5–12, and Figure 6D). ARE2 overexpression did
not have any effect on the conversion of ceramide into its esters
(results not shown), although its overexpression leads to a rapid
appearance of LDs in an are1are2lro1dga1 background
[29].
Signiﬁcantly, all of these cell lines growing on glucose made
very few acylceramides. This indicates that Lro1p and Dga1p are
the only enzymes that can acylate the ceramide in living cells.
The quantiﬁcation of the presumed acylceramides was always
done by subtracting mild-base-resistant counts from total counts
in the acylceramide band of the untreated sample (see the
Experimental section). Calculated in this way, 7% of the total
incorporated radioactivity was present as acylceramide when
DGA1 was overexpressed, and only 2% when LRO1 was
overexpressed (Figure 6D). In WT cells acylceramides amounted
usually to approximately 2–5% of total labelled lipids. In other
words, a quarter of the total ceramides was usually esteriﬁed in
WT cells (Figure 6D).
Characterization of [14C]serine-labelled acylceramides
To obtain additional evidence for the biosynthesis of acylceramide
in vivo we also labelled cells with [14C]serine in the presence of
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Figure 7 The main ceramides acylated in WT cells in vivo co-migrate with
DHS-C26 and PHS-C26-OH
(A) WT cells were cultured with or without 40 μg/ml myriocin (MYR) for 2 h. Then the cells were
labelled with [14C]serine for 160 min at 30◦C in the same medium as used for pre-incubation.
The extracted lipids were treated and resolved by TLC. (B) WT cells were grown at 30◦C and
labelled with [14C]serine for 2 h at the same temperature. The labelled lipids were resolved by
TLC resulting in the proﬁle in lane 1. The main ceramides and acylceramides were scraped off
of the TLC plate, extracted from the silica and subjected to mild base hydrolysis with sodium
hydroxide or mock-treated. Horizontal arrows connect identical lipids before and after scraping.
The sodium-hydroxide-resistant lipid co-migrating with acylceramide is marked as ‘X’. The
Figure shows one of three experiments which gave similar results. The quantiﬁcation of all three
experiments is given in Table 3. (C) scs7Δ and WT cells were labelled with [14C]serine and
lipid extracts were analysed by TLC. Cer, ceramide; o, origin.
myriocin, a speciﬁc inhibitor of the serine palmitoyl transferase
catalysing the ﬁrst step of sphingolipid biosynthesis. The
synthesis of ceramides and acylceramide was strongly repressed
by myriocin (Figure 7A). This further conﬁrmed that the very
hydrophobic labelled lipids observed after metabolic labelling
with [14C]serine are indeed derived from sphingolipids, the
biosynthesis of which requires LCB1. A similar reduction of
ceramide and acylceramide biosynthesis was also observed in
the thermosensitive lcb1-100 cells, labelled at 37 ◦C (results not
shown).
Yeast ceramides either contain DHS or PHS, and their fatty
acid can be either non-, mono- or bis-hydroxylated [30,31]. The
most abundant ceramide of yeast is phytoceramide containing an
α-hydroxylated C26:0 fatty acid (PHS-C26-OH) [18,32]. To ﬁnd out
what ceramides became acylated, and to corroborate the idea that
the most hydrophobic [14C]serine-labelled lipids in Figure 6 are
acylceramides, such lipids were scraped off of the TLC plate and
treated with mild base. Acylceramide from WT cells contained
on average 40% of a lipid running with PHS-C26-OH and 30%
of a lipid running with DHS-C26, the remainder being mild base
resistant for unknown reasons (see above) (Figure 7B andTable 3).
To see whether PHS-C26-type ceramides can also be acylated,
we also labelled the scs7Δ strain, lacking the fatty acid
hydroxylase [31] (Figure 7C). Metabolic labelling of scs7Δ with
[14C]serine yielded a major band in the region of acylceramides,
Table 3 Quantiﬁcation of deacylation products of [14C]serine-labelled
acylceramides
The abundance of different lipids in lane 7 of Figure 7(B) and in two similar experiments is
expressed as a percentage of total lipids after mild base treatment.
Experiment number
Deacetylation product 1 2 3 1–3 mean (S.D.)
X (sodium-hydroxide-resistant) 23.1% 38.9% 27.7% 29.9% (8.1)
DHS-C26 37.9% 37.9% 15.4% 30.4% (13.0)
PHS-C26-OH 38.9% 23.3% 56.9% 39.7% (16.8)
a large fraction of which was hydrolysed to lipids running with
DHS-C26 and PHS-C26, the latter being the main ceramide of
this strain [31]. Thus the deletion of SCS7 does not prevent the
biosynthesis of acylceramides and suggests that, although PHS-
C26 is not efﬁciently acylated inWT cells, the acyltransferases can
utilize it in a scs7Δ background and that the resulting acylated
PHS-C26 is stable.
In view of the variability of the relative amounts of
acylceramides observed in our experiments and in view of the
known ability of yeast cells to secrete apolar lipids, such
as acetylated cholesterol [33], we tested whether yeast cells
would secrete any acylceramide. However, when analysing the
growth medium we could not detect any secreted acylceramides
(Supplementary Figure S4A at http://www.BiochemJ.org/bj/447/
bj4470103add.htm).
Acylceramides can be mobilized when fatty acid synthesis
is compromised
We also wondered whether an increased demand for fatty
acids inducing the disappearance of LDs could lead to the
hydrolysis of acylceramides. To test for this we utilized conditions
in which high amounts of acylceramide were available for
degradation. DGA1 and LRO1 were simultaneously induced
in are1are2lro1.DGA1.LRO1 cells in galactose-containing
medium and cells were at the same time labelled with [14C]serine
for 16 h (Figure 8A). Chasing in fresh glucose medium,
allowing for repression of DGA1 and LRO1, did not result
in mobilization of acylceramides as compared with the simple
continuation of the culture in the labelling medium (Figure 8A,
condition 2 compared with condition 1, and Figure 8B). On the
other hand, chasing with glucose medium supplemented with the
fatty acid synthase inhibitor cerulenin led to the almost complete
disappearance of acylceramides within 6 h (Figure 8A, condition
3, and Figure 8B). It is worth noting that, in Figure 8, acylceram-
ides were labelled in the absence of cycloheximide. Indeed, this
drug enhances incorporation of [14C]serine into lipids, but acylcer-
amides are also made in its absence (Supplementary Figure S4B).
We also tried to force the mobilization of acylceramides
by inﬂicting a want of sphingolipids. For this, cells were
labelled with [14C]serine for 12 h and chased for the indicated
periods with non-radioactive serine in the presence of myriocin
(Figure 8C). WT cells were used in this experiment as well
as a strain deﬁcient in Isc1p, the only enzyme in yeast able
to hydrolyse IPCs [34,35]. In isc1Δ mutants the pathway
generating ceramides via the breakdownof complex sphingolipids
is blocked (Figure 1). TLC analysis did not show any signiﬁcant
mobilization of acylceramide during chase in both WT and isc1Δ
(Figure 8C) cells, and the quantiﬁcation by Berthold scanning
conﬁrmed this impression (Supplementary Figrues S5A and
S5B at http://www.BiochemJ.org/bj/447/bj4470103add.htm, red
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Figure 8 Disappearance of acylceramides under drug-induced lipid deprivation
(A) are1are2dga1.DGA1 cells bearing DGA1 behind the GAL1 promoter were grown overnight to a D600 of 3.0 in galactose medium while being labelled with [14C]serine at 30◦C (16 h
labelling). On the next day, the cell culture was split into three equal parts and treated as follows. Condition 1, culture of cells in the presence of [14C]serine was simply continued for a further 6 h
without changing the medium; condition 2, cells were collected, washed and further incubated in an equal volume of fresh medium without [14C]serine containing glucose as a carbon source (CS)
for 6 h; condition 3, as for condition 2, but the medium was supplemented with 10 μg/ml cerulenin (CER). Extracted lipids were resolved by TLC. (B) Quantiﬁcation of data in (A) was expressed
as absolute counts present in the various lipid species on the Berthold scan. (C) WT and isc1Δ cells were labelled with [14C]serine for 12 h at 30◦C to a D600 of 8.0. After labelling, cells were
collected, washed and resuspended at a D600 of 1.0 in YPD medium supplemented with 7 mg/ml serine and 40 μg/ml myriocin. Cells were chased at 30◦C and a ﬁxed volume of culture was
removed for lipid analysis after 0, 1, 3 or 7 h. Lipids were extracted and treated as described above. Quantiﬁcation of some lipid species during chase are shown in Supplementary Figure S5 (at
http://www.BiochemJ.org/bj/447/bj4470103add.htm). Cer, ceramide; gal, galactose; glc, glucose; o, origin.
columns). Indeed, the lipid proﬁles in WT and isc1Δ cells were
very similar. Thus it appears that an acute lack of sphingolipids
does not induce a mobilization of the ceramide moiety of
acylceramides.
DISCUSSION
This present paper discusses the existence of a metabolic
pathway in yeast, which previously had been characterized in
mammalian cells. It allows ceramides to not only be processed
for IPC biosynthesis or degradation via the ceramidases, but
also to be transformed into acylceramides as shown in Figure 1.
Acylceramides, as judged by their physicochemical properties,
could well be deposited in LDs, although this will have to be
tested experimentally. At the moment it is not clear whether this
pathway represents a mere detoxiciﬁcation mechanism to protect
cells from toxic amounts of ceramides or fatty acids [36], or
whether it also serves a storage purpose, similar to TAGs, which
are mobilized to allow for rapid membrane biosynthesis when
stationary phase cells are diluted into nutrient-rich media and
resume growth [37].
The acylceramides seem to be made by Lro1p and Dga1p,
the former being the only enzyme showing activity in our
microsomal in vitro system. In intact cells Dga1p also seems
to be able to acylate ceramides, according to metabolic labelling
experiments. It thus appears that Dga1p and Lro1p can utilize
ceramide instead of DAG, but it is difﬁcult to estimate the relative
contributions of these enzymes from our experiments, because
the demonstration that either enzyme can acylate ceramides in
living cells was performed in cells overexpressing either Lro1p or
Dga1p (Figure 6C).
Dga1p and Lro1p were previously shown to have relaxed
substrate speciﬁcity in that they can also use monoacylglycerol
and long-chain alcohols as an acceptor substrate [38,39],
although they cannot use ergosterol [16,40]. It has been reported
that in microsomal assays Lro1p uses PE and PC as donor
substrates, transfers saturated, unsaturated and even the non-
natural polyunsaturated fatty acids groups and may transfer fatty
acids also from the sn-1 position, albeit at an approximately 10-
fold lower rate than from the sn-2 position; it can even use DAG
as a donor substrate [15,38].
We were able to show that microsomes attach O-acyls to
the position 1 of sphingosine-containing ceramides using DDQ
oxidation (Figure 4). We tried to conﬁrm this result by testing
whether ceramides lacking the hydroxy group on C1 or lacking
the hydroxylated C1 atom altogether could still be acylated. For
this we added to microsomes [3H]C16:0 plus 1-deoxysphinganine
or 1-deoxymethylsphingosine, lacking the terminal OH- or OH-
CH2- group of classical LCBs, but these LCB analogues were
not recognized as substrates by Ypc1p, and no corresponding
1-deoxy- or 1-deoxymethyl-[3H]ceramides were generated in our
microsomal in vitro system (results not shown).Ypc1p also did not
recognize 3-oxo-sphinganine (results not shown). Thus we could
not conﬁrm that the O-acylation of DHS- and PHS-containing
ceramides occurs on C1 using these approaches.
In our TLC system the deacylation products of the in-
vivo-generated acylceramides mainly ran at the positions of
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DHS-C26 and PHS-C26-OH, whereas almost no material co-
migrating with PHS-C26-OH appeared upon deacylation of
acylceramides of the scs7Δmutant lacking fatty acid hydroxylase
(Figure 7C). Although this suggests that Dga1p and Lro1p mainly
acylate DHS-C26 and PHS-C26-OH, other ceramides may run to
the same position on TLC. For instance, the position in this TLC
system of the previously described PHS-C14-OH species [32] is
unknown. Clearly more studies are required to identify the exact
nature of the ceramide species acylated in living cells.
Lro1p is the only yeast homologue of the mammalian
LPLA2, the ﬁrst and only other enzyme reported to acylate
ceramides on C1 [23,25,41]. The enzyme is a group XV
PLA2, and is a close homologue of the extracellular LCAT of
high-density lipoproteins. Although LPLA2 seems to function
predominantly as a lysosomal acid phospholipase, it can, as many
phospholipases, also act as a transacylase in the presence of
suitable acceptor substrates. As (donor) substrates it prefers PE
and PC and, contrary to its name, can release fatty acids from
both sn-2 and sn-1 positions [42]. The acceptor speciﬁcity of
LPLA2 is broad, and many long-chain hydrocarbons possessing
a primary alcoholic group can be used as substrates [23]. As far
as ceramides are concerned, the best substrate in in vitro reactions
was N-acetyl-sphingosine, and much less activity was found with
N-octanoyl- or N-stearyl-sphingosine as substrates [25]. Whether
LPLA2 in vivo uses conventional ceramides with fatty acids of
14–24 carbon atoms is not clear.
Lro1p, LCAT and PLAL2 are homologues and, according to
the conserved domains database at NCBI (http://www.ncbi.nlm.
nih.gov/cdd/), they all have numerous identities with the 377
residues long pfam02450 consensus sequence over its entire
length. Lro1p, LCAT and LPLA2 all contain a catalytic serine-
histidine-aspartate triad; the ﬁrst two in addition also contain
a serine lipase motif [VxL(I/V)GHSxG] [13,43]. In analogy to
LCAT and LPLA2, which are active extracellularly and in the
lysosome respectively, the catalytic residues of Lro1p also lie
outside the cytoplasm, namely in the ER lumen. Indeed, Lro1p
consists of a type II integral membrane glycoprotein with a single
transmembrane helix [44]. Ceramides and DAGs therefore need
to reach the ER lumen in order to get access to its catalytic site.
Metabolic labelling with [14C]serine suggests that some newly
made ceramidesmay be channeled into acylceramide biosynthesis
and that they can be remobilized in the presence of cerulenin
(Figure 8). It is not clear at present what enzymes hydrolyse
the O-acyl group of acylceramides, and also it cannot be
decided whether cerulenin mobilizes acylceramides by activating
certain hydrolases or whether the mobilization is simply due to
the disappearance of LDs [12]. Disappearance of LDs might
bring acylceramides into contact with ER-localized hydrolases.
Whatever the mechanism, the fact that acylceramides remain
stable in the absence of cerulenin but start to disappear in its
presence (Figure 8A, lanes 1 and 2 compared with lanes 5 and 6,
and Figure 8B) does suggest that acylceramide breakdown may
somehow be regulated.
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Figure S1 Dga1p does not contribute signiﬁcantly to microsomal
acylceramide synthesis in vitro
Microsomes of lro1Δ cells overexpressing YPC1 (lro1.YPC1) were incubated with PHS and
[3H]palmitate to allow Ypc1p-driven ceramide synthesis to take place as in Figure 2(A), lane 8
of the main text. After a 1 h incubation, the reaction mixture was supplemented with different
acyl-CoAs as indicated and samples were incubated for a further 1 h in conditions that are
appropriate for Dga1p-mediated TAG synthesis. Lipids were extracted and resolved by TLC.
Boiled microsomes were used for the incubation shown in lane 9. Cer, ceramide.
1 To whom correspondence should be addressed (email andreas.conzelmann@unifr.ch).
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Figure S2 Structural analysis of C18:1-C6–NBD–DHS by ion-trap MS/MS
C18:1-C6–NBD–DHS ion at m/z 840.6215 detected in microsomes from wild-type cells incubated with C6–NBD–DHS (Figure 5B of the main text) was subjected to collision-induced dissociation.
The m/z of fragment ions in the resulting MS/MS spectrum conﬁrm the identity of the C18:1-C6–NBD–DHS molecule as outlined in the fragmentation scheme.
Figure S3 Galactose induces overexpression of LRO1 or DGA1
Total cell lysate was prepared from are1are2lro1.DGA1 (.DGA1),
are1are2dga1.LRO1 (.LRO1) and WT strains grown overnight in galactose for
the experiment shown in Figure 6(C) of the main text. The proteins were resolved by SDS/PAGE
and detected by Western blotting using an anti-GFP antibody. The bands at 102 kDa and 74 kDa
correspond to Lro1p–GFP andDga1p–GFP respectively. Themolecularmass in kDa is indicated.
gal, galactose; glc, glucose.
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Figure S4 Acylceramides are not secreted and also made in the absence of cycloheximide
(A) Cells do not secrete acylceramides. WT cells were labelled with [14C]serine in the presence of 5 mg/ml fatty-acid-free BSA for 160 min. The labelled lipids were extracted from cells and from
medium; extracts were desalted, deacylated or not with sodium hydroxide and resolved by TLC. The Figure shows one of two experiments, which gave identical results. (B) CHX does not change the
lipid proﬁle of cells labelled with [14C]serine. WT cells were labelled with [14C]serine in medium supplemented with or without 10 μg/ml CHX for 160 min at 30◦C. The extracted lipids were treated
or not with mild base and resolved by TLC. The relative amounts of acylceramides and ceramides are shown on the right-hand side. Cer, ceramide; o, origin.
Figure S5 Quantiﬁcation of TLC shown in Figure 8(C) of the main text
Berthold radioscanning yielded counts for each labelled species after 0, 1, 4 and 7 h of chase in the presence of myriocin. Counts were plotted without any background subtraction except for
acylceramides, for which the counts in the mild-base-resistant lanes at the Rf of acylceramides and the Rf of fatty acids were subtracted. (A) isc1 cells. (B) WT cells.
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